Skip to main content
    O

    Ocular Therapeutix Inc (OCUL)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $6.02
    +0.01 (+0.17%)

    Market Cap: $1.37B

    Last updated: Nov 17, 2026 at 4:15 PM ET

    Ocular Therapeutix Inc (OCUL) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Ocular Therapeutix (OCUL) has a market cap of $1.37B and an enterprise value of $909.26M. It kept -648.64% of revenue as net income over the last 12 months. Its share count is up 22.62% from a year earlier.

    Total Valuation

    Enterprise value is 33.45% below the market cap, as cash exceeds debt.

    Market Cap$1.37B
    Enterprise Value$909.26M
    Latest price (Nov 17, 2026)$6.02

    Key Dates

    The next earnings report is expected on Feb 3, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 3, 2027 (expected)
    Last Earnings DateNov 9, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.25% in the quarter ended Sep 30, 2026 and grew 16.21% a year over 2 years.

    Shares Outstanding225.52M
    Shares Change (YoY)+22.62%
    Shares Change (QoQ)+0.25%
    Share Count Growth (2Y CAGR)+16.21%

    Valuation Ratios

    Sales and book value multiples are 26.9x and 3.1x. Its year-end P/S ranged from 4.3x to 110.1x from 2016 to 2025.

    P/S Ratio26.9x
    Forward P/S26.8x
    P/B Ratio3.1x

    Valuation history and multiples

    Price Statistics

    The stock is down 46.73% over 52 weeks and trades 22.72% below its 50-day average.

    Beta (1Y)1.43
    52-Week Change-46.73%
    1-Month Change-4.29%
    3-Month Change-48.68%
    6-Month Change-24.66%
    5-Year Change+4.97%
    10-Year Change+23.14%
    Total Return (1Y)-46.73%
    Total Return (3Y CAGR)+38.20%
    Total Return (5Y CAGR)-2.15%
    Return vs SPY (1Y)-60.37%
    Max Drawdown (1Y)-62.69%
    Max Drawdown (3Y)-62.69%
    Sharpe Ratio (1Y)-0.89
    Correlation with SPY (1Y)0.26
    50-Day Average$7.79
    200-Day Average$8.87
    52-Week Range$5.94 to $16.44
    RSI (14 Days)35.7
    Average Volume (20 Days)2.71M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 9.12x current liabilities, and total debt is 0.17x shareholder equity.

    Current Ratio9.12x
    Quick Ratio9.05x
    Debt / Equity0.17x
    Interest Coverage-30.26x

    Returns and Efficiency

    Return on invested capital is -52.12% over the last 12 months, against a 5-year average of -29.67%.

    Return on Equity (ROE)-74.12%
    Return on Assets (ROA)-53.96%
    Return on Invested Capital (ROIC)-52.12%
    ROE (5Y Average)-79.77%
    ROA (5Y Average)-31.60%
    ROIC (5Y Average)-29.67%
    Asset Turnover0.10x
    Inventory Turnover1.58x
    Receivables Turnover1.63x
    Cash Conversion Cycle90 days

    Scores

    OCUL has an Altman Z-Score of 0.91, in the distress zone below 1.81, and a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.

    Altman Z-Score0.91
    Altman Z ZoneDistress
    Piotroski F-Score4 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $50.38M over the last 12 months is down 9.68% from the 12 months before.

    Revenue$50.38M
    Revenue Growth (YoY)-9.68%
    Gross Profit$43.99M
    Operating Income-$343.07M
    Pretax Income-$326.84M
    Net Income-$326.81M
    Reported EPS (TTM)-$1.46

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 72.81% of the $605.65M in total assets.

    Cash and Equivalents$530.61M
    Total Debt$73.53M
    Net Cash$457.08M
    Net Cash Per Share$2.03
    Working Capital$511.58M
    Shareholder Equity$440.95M
    Book Value Per Share$1.96
    Total Assets$605.65M
    Total Liabilities$164.70M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $13.90M of capital spending, operating cash flow left -$267.04M of free cash flow.

    Operating Cash Flow-$253.14M
    Capital Expenditures$13.90M
    Free Cash Flow-$267.04M
    FCF Per Share-$1.22
    Depreciation and Amortization$9.95M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -680.91%.

    Gross Margin87.32%
    Operating Margin-680.91%
    Pretax Margin-648.70%
    Net Margin-648.64%
    FCF Margin-530.00%
    Gross Margin (5Y Average)90.11%

    Growth

    Revenue grew 0.29% a year over 3 years.

    Revenue Growth (3Y CAGR)+0.29%
    Revenue Growth (5Y CAGR)+24.45%
    Book Value Per Share Growth (2Y CAGR)+87.20%
    Tangible Book Per Share Growth (2Y CAGR)+87.20%

    Revenue and profit by year

    Dividends and Yields

    OCUL does not pay a dividend. Its free cash flow yield is -19.67%.

    FCF Yield-19.67%
    Buyback Yield-0.06%
    Shareholder Yield-0.06%

    Peer Position

    Against 6 similar companies, OCUL has the 3rd highest P/S.

    P/S Ratio26.9x vs 19.1x median
    ROIC-52.12% vs -51.14% median
    Revenue Growth (Trailing 4 Quarters, YoY)-9.68% vs -99.31% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 32.48% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+32.48%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About OCUL

    What is OCUL's market cap?

    Ocular Therapeutix has a market cap of $1.37B. Its enterprise value, which adds debt and subtracts cash, is $909.26M.

    How many shares of OCUL are outstanding?

    Ocular Therapeutix has 225.52M shares outstanding. The count is up 22.62% from a year earlier.

    Does OCUL pay a dividend?

    No. Ocular Therapeutix does not pay a dividend.

    How much debt does OCUL have?

    Ocular Therapeutix has $73.53M of total debt and $530.61M of cash and equivalents, a net cash position of $457.08M.